Autobahn Therapeutics Receives FDA Fast Track Designation for Elunetirom in Bipolar Depression
核心洞察
The FDA granted Fast Track designation to elunetirom (搜索), an oral CNS thyroid hormone receptor (搜索) agonist, for adjunctive treatment of bipolar depression (搜索) in adults.
Elunetirom (搜索) represents a novel mechanism targeting brain energy and plasticity through mitochondrial health improvement and neuroplastic changes in the CNS.
The Phase 2 AMPLIFY-BD trial for bipolar depression (搜索) is ongoing with topline data expected in Q2 2026, addressing a condition affecting 7 million U.S. adults.
Autobahn Therapeutics (搜索) announced that the U.S. Food and Drug Administration has granted Fast Track designation to elunetirom (搜索), the company's lead CNS thyroid hormone receptor (搜索) agonist, for the adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder (搜索) in adults. The designation recognizes elunetirom's potential to address significant unmet medical needs in a patient population where current treatment options remain inadequate.
Novel Mechanism Targets Brain Energy and Plasticity
Elunetirom (搜索) (ABX-002) is an investigational, oral, once-daily, brain-penetrant small molecule prodrug that targets CNS thyroid hormone receptors. The compound is designed to boost energy and plasticity in the brain through improving mitochondrial health, increasing cellular energy production, and driving neuroplastic changes in the central nervous system.
"Elunetirom (搜索) represents a fundamentally new treatment approach with a differentiated profile designed to enable better care for patients," said Kevin Finney, President and Chief Executive Officer of Autobahn Therapeutics (搜索). The drug is engineered to enhance beneficial neurobiological activity at CNS thyroid hormone receptors while reducing the peripheral liabilities associated with synthetic thyroid hormone administration.
Addressing Critical Unmet Medical Need
Bipolar depression (搜索) affects approximately 7 million adults in the United States and represents one of the most disabling indications in psychiatry, where patients lose an average of more than one month of work each year. More than half of patients do not receive adequate relief on currently available therapies, which are limited by modest efficacy and significant side effects, including weight gain, sexual dysfunction, movement disorders, and metabolic complications.
"The standard of care in bipolar depression (搜索) hasn't meaningfully changed in decades, and patients continue to have to choose between inadequate relief and unacceptable side effects," Finney noted.
Clinical Development Progress
Autobahn is conducting the Phase 2 AMPLIFY-BD trial (NCT06869187) for adjunctive bipolar depression (搜索) treatment, with topline data expected in the second quarter of 2026. The company is also developing elunetirom (搜索) as an adjunctive treatment for major depressive disorder (搜索) in its ongoing Phase 2 AMPLIFY trial (NCT06633016), with topline data anticipated in the third quarter of 2026.
In nonclinical and clinical studies, elunetirom (搜索) has demonstrated optimized pharmacokinetic properties, target engagement in brain regions associated with depression, and an acceptable safety and tolerability profile.
Regulatory Pathway Advantages
"The receipt of Fast Track is an important advancement in our efforts to bring elunetirom (搜索) to patients suffering from bipolar depression (搜索)," said Alida Barry, Vice President, Head of Regulatory Affairs at Autobahn Therapeutics (搜索). Fast Track designation is granted to investigational treatments that may offer substantial benefit over currently available options for serious conditions with unmet needs.
The FDA's Fast Track program facilitates development and expedites review of investigational therapies for serious conditions. Drugs receiving this designation are eligible for more frequent FDA communication throughout development and potential Accelerated Approval, Priority Review, and Rolling Review of marketing applications if relevant criteria are met.